Skip to main content
. 2014 Mar 5;34(10):3467–3474. doi: 10.1523/JNEUROSCI.3861-13.2014

Figure 3.

Figure 3.

Mean (+SEM) distance traveled (cm) of animals during a 15 min locomotor activity test conducted under the influence of intracranial infused Vehicle into the CeA (n = 6) or the BNST (n = 5) or the High Dose (1.0 nmol) of each of the 2 NE β-antagonists delivered bilaterally (0.5 μl/side) into the CeA (n = 6) or BNST (n = 6). ANOVA confirmed that intracranial NE antagonist treatment had no reliable impact on spontaneous locomotor activity.